Teyi Pharmaceutical Group Co.,Ltd (SHE:002728)
China
· Delayed Price · Currency is CNY 9.93
0.00 (0.00%)
Apr 30, 2026, 3:04 PM CST
SHE:002728 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 923.81 | 686.91 | 1,066 | 886.15 | 757.93 | Upgrade
|
| Other Revenue | 0.72 | 0.88 | 0.74 | 0.43 | 0.23 | Upgrade
|
| Revenue | 924.53 | 687.79 | 1,067 | 886.57 | 758.16 | Upgrade
|
| Revenue Growth (YoY) | 34.42% | -35.55% | 20.38% | 16.94% | 19.83% | Upgrade
|
| Cost of Revenue | 421.17 | 386.47 | 467.98 | 451.83 | 356.12 | Upgrade
|
| Gross Profit | 503.36 | 301.32 | 599.23 | 434.74 | 402.04 | Upgrade
|
| Selling, General & Admin | 371.5 | 225.54 | 240.67 | 176.38 | 175.95 | Upgrade
|
| Research & Development | 44.41 | 43.33 | 43.06 | 38.01 | 37.78 | Upgrade
|
| Other Operating Expenses | 7.91 | 2.05 | 9.38 | 1.75 | 9.27 | Upgrade
|
| Operating Expenses | 422.54 | 270.89 | 293.19 | 216.74 | 224.72 | Upgrade
|
| Operating Income | 80.82 | 30.43 | 306.04 | 217.99 | 177.33 | Upgrade
|
| Interest Expense | -4.23 | -5.32 | -16.36 | -29.13 | -29.51 | Upgrade
|
| Interest & Investment Income | 3.57 | 10.34 | 12.34 | 8.55 | 12.14 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.37 | -0.45 | -0.4 | -1.44 | -0.42 | Upgrade
|
| EBT Excluding Unusual Items | 80.53 | 34.99 | 301.61 | 195.97 | 159.53 | Upgrade
|
| Impairment of Goodwill | - | -11.63 | -13.17 | - | -23.06 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.07 | 0.01 | 0.12 | 0.04 | 0.1 | Upgrade
|
| Asset Writedown | -0.82 | -0.16 | -0.27 | -0.12 | -0.37 | Upgrade
|
| Other Unusual Items | 2.64 | -1.16 | 4.7 | 0.43 | 10.91 | Upgrade
|
| Pretax Income | 82.28 | 22.05 | 292.99 | 196.32 | 147.1 | Upgrade
|
| Income Tax Expense | 0.61 | 1.56 | 39.82 | 18.12 | 20.18 | Upgrade
|
| Net Income | 81.67 | 20.5 | 253.18 | 178.2 | 126.92 | Upgrade
|
| Net Income to Common | 81.67 | 20.5 | 253.18 | 178.2 | 126.92 | Upgrade
|
| Net Income Growth | 298.50% | -91.91% | 42.07% | 40.41% | 189.66% | Upgrade
|
| Shares Outstanding (Basic) | 510 | 512 | 460 | 438 | 401 | Upgrade
|
| Shares Outstanding (Diluted) | 510 | 512 | 460 | 438 | 401 | Upgrade
|
| Shares Change (YoY) | -0.38% | 11.31% | 5.16% | 9.09% | 2.75% | Upgrade
|
| EPS (Basic) | 0.16 | 0.04 | 0.55 | 0.41 | 0.32 | Upgrade
|
| EPS (Diluted) | 0.16 | 0.04 | 0.55 | 0.41 | 0.32 | Upgrade
|
| EPS Growth | 300.00% | -92.73% | 35.10% | 28.71% | 181.91% | Upgrade
|
| Free Cash Flow | 164.54 | -136.11 | 112.51 | 281.39 | 147.24 | Upgrade
|
| Free Cash Flow Per Share | 0.32 | -0.27 | 0.24 | 0.64 | 0.37 | Upgrade
|
| Dividend Per Share | 0.150 | 0.050 | 0.357 | 0.332 | 0.332 | Upgrade
|
| Dividend Growth | 200.00% | -86.00% | 7.69% | - | - | Upgrade
|
| Gross Margin | 54.45% | 43.81% | 56.15% | 49.04% | 53.03% | Upgrade
|
| Operating Margin | 8.74% | 4.42% | 28.68% | 24.59% | 23.39% | Upgrade
|
| Profit Margin | 8.83% | 2.98% | 23.72% | 20.10% | 16.74% | Upgrade
|
| Free Cash Flow Margin | 17.80% | -19.79% | 10.54% | 31.74% | 19.42% | Upgrade
|
| EBITDA | 150.64 | 94.79 | 366.14 | 270.52 | 228.63 | Upgrade
|
| EBITDA Margin | 16.29% | 13.78% | 34.31% | 30.51% | 30.16% | Upgrade
|
| D&A For EBITDA | 69.82 | 64.37 | 60.1 | 52.52 | 51.31 | Upgrade
|
| EBIT | 80.82 | 30.43 | 306.04 | 217.99 | 177.33 | Upgrade
|
| EBIT Margin | 8.74% | 4.42% | 28.68% | 24.59% | 23.39% | Upgrade
|
| Effective Tax Rate | 0.74% | 7.06% | 13.59% | 9.23% | 13.72% | Upgrade
|
| Revenue as Reported | 924.53 | 687.79 | 1,067 | 886.57 | 758.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.